You must have the latest - Flash plugin - to view this slideshow. 63-year history of research and clinical excellence

U.S. News and World Report ranks Dana-Farber/Brigham and Women’s Cancer Center the top cancer hospital in New England; fourth in U.S.

July 15, 2014

U.S. News and World Report ranks Dana-Farber/Brigham and Women's Cancer Center the top hospital in New England for the 14th straight year.

Magnet Logo 

Dana-Farber Cancer Institute recognized as a Magnet® organization for excellence in nursing and patient care

July 16, 2014

Dana-Farber Cancer Institute has earned Magnet® status from the American Nurses Credentialing Center (ANCC) for the third time. This prestigious designation recognizes excellence in nursing and health care delivery.
 

Matthew Meyerson, MD, PhD in the lab 

Nineteen Dana-Farber scientists listed among world's most influential

July 01, 2014

In an affirmation of worldwide respect for the impact of Dana-Farber research, 19 basic scientists and clinical investigators at the Institute have been listed among "the world's most influential scientific minds." The ranking was based on how frequently their research discoveries have been cited by peers in the past decade.
 

Dana-Farber Cancer Institute recognized as a Magnet® organization for excellence in nursing and patient care
July 16, 2014

Dana-Farber Cancer Institute is recognized as a Magnet® organization for excellence in nursing and patient care for the third time.

Antibody halts cancer-related wasting condition
July 13, 2014

Dana-Farber scientists identify a protein that is a cause of cachexia, a severe wasting of fat and muscle in half of all cancer patients, and show that blocking the protein in mice can prevent or halt the debilitating condition.

Study identifies novel genomic changes in the most common type of lung cancer
July 09, 2014

Dana-Farber and colleagues from the Cancer Genome Atlas (TCGA) Research Network identified novel mutations in a well-known cancer-causing pathway in lung adenocarcinoma, potentially identifying a greater number of patients with treatable mutations because many potent cancer drugs that target these mutations already exist. Additionally, these findings may expand the number of possible new therapeutic targets for this disease.

U.S. News & World Report Announces 2014-15 Best Hospitals Rankings (U.S. News & World Report)

July 15, 2014

The U.S. News and World Report Best Hospitals Guide has ranked Dana-Farber/Brigham and Women's Cancer Center the highest in New England for cancer care for the 14th straight year and fourth overall in the country.

Study Discounts Testosterone Therapy for Early Prostate Cancer (The New York Times)
July 14, 2014

An editorial written by physicians at Dana-Farber supports a study showing there is no compelling evidence to justify using testosterone suppression therapy on men with early-stage prostate cancer.

Ado-Trastuzumab Emtansine Improves Progression-Free Survival vs Physician’s Choice in Advanced HER2-Positive Breast Cancer (ASCO Post)
July 10, 2014

Dr. Ian E. Krop led a study showing that the anti-body drug ado-trastuzumab emtansine significantly prolonged progression-free survival in patients with progressive HER2-positive advanced breast cancer.

ASCO Clinical Practice Guideline: Disease Management in Advanced HER2-Positive Breast Cancer With Brain Metastases (ASCO Post)
July 10, 2014

Dr. Eric P. Winer co-chaired an expert panel that developed a clinical practice guideline on disease management for patients with advanced HER2-positive breast cancer and brain metastases.

Scientists publish a deep look at DNA mutations in lung cancer (Boston Globe)
July 10, 2014

Dr. Matthew Meyerson led a genomic study of lung cancer which has provided information that could help scientists devise new treatments.

Prostate Cancer Outcomes May Improve Under Affordable Care Act (Renal & Urology News)
July 07, 2014

Dr. Paul L. Nguyen led a study showing prostate cancer patients with health insurance are less likely to have metastatic disease or die from the cancer than those without health insurance.

JPMorgan's Dimon has throat cancer, to begin treatment shortly (Reuters)
July 02, 2014

Dr. Robert Haddad commented on JPMorgan Chase CEO Jamie Dimon being diagnosed with throat cancer.

Sunset Qigong

July 22, 2014

4:30 PM - 6:00 PM

Smith Room 330, Stoneman Patient Services Suite

Fine tune your mind/body skills and create balance among them. Open to patients and family members. Please register at 617-632-3322. more

Melanoma Support Group(6)

July 22, 2014

5:30 PM - 7:00 PM

Smith 330

This group offers you can opportunity to develop a peer network of shared understanding and support in a setting where you can discuss;

  • Thought, concerns, experiences
  • Communicating with family, friends , co-workers
  • Ways of Coping

Pre-registration is required: To register or for more info: Contact Nancy Bailey at 617-632-3599

 

Deaconess Medical Center. Call Frank McCaffrey 617 667-3525

more

Dana-Farber's Mammography Van(17)

July 23, 2014

The Dimock Center

Dana-Farber's Mammography Van brings state-of-the-art breast cancer screening to the women of Greater Boston.  To learn more or schedule an appointment, please call 617-632-1974. more

  •  
  • Patient referral information, clinical resources and more.

  • Make an Appointment


    For adults:
    877-442-3324

    For children:
    888-733-4662


    Or complete the online form.

  • Clinical Trials

    Search current cancer clinical trials at Dana-Farber.

  • How to Help

    Yawkey Center for Cancer Care entrance 

    There are many ways to support Dana-Farber and the Jimmy Fund.

    give now button
  • Dana-Farber Blog

    Insight Blog screenshot 

    Insight features the latest in cancer care and research news from Dana-Farber.
    Read the blog

  • Dana-Farber eNewsletter

    Dana-Farber Spotlight 

    Stay current on the latest news by signing up for Spotlight, our email newsletter.
    View current issue
    Subscribe now